Simplify Logo

Full-Time

Associate Director

Quality Systems

Posted on 3/22/2024

Cytokinetics

Cytokinetics

201-500 employees

Develops muscle function drugs for diseases

Hardware
Biotechnology
Healthcare

Senior, Expert

San Bruno, CA, USA

Category
Diagnostics & Laboratory Professionals
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Bachelor's degree in a scientific field
  • 10+ years experience in a biopharmaceutical, pharmaceutical, biologics, or related life sciences area
  • Knowledge of GXP regulations and guidelines
  • Ability to work with ambiguity and creative problem-solving
  • Strong interpersonal and communication skills
Responsibilities
  • Design, develop, and deploy quality systems in accordance with ICH Q10 model
  • Contribute to the strategic roadmap for the Quality Systems group
  • Lead various aspects of the Quality Systems and ensure compliance with company procedures and regulatory guidelines
  • Define strategy and execute continuous improvement opportunities within Quality Systems
  • Act as subject matter expert and provide guidance on quality events
  • Establish and implement risk management program
  • Lead quality governance board meetings
  • Oversee and manage the electronic quality management system
  • Supervise employees, consultants/contractors, and interns

Cytokinetics is a late-stage biopharmaceutical company focused on developing small molecule muscle activators and inhibitors to address impaired muscle function in conditions such as heart failure, hypertrophic cardiomyopathy, and neuromuscular diseases. The company's main technologies involve engineering drug candidates to impact muscle function and contractility, with the goal of discovering, developing, and commercializing potential treatments for debilitating diseases.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

28%
INACTIVE